Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan, US, Europe Trade Groups Forge United Front against Govt PMP Plan, Supportive of Negative List: Chuikyo
November 30, 2017
-
BUSINESS Japan’s 1st Rituxan Biosimilar to Arrive Soon, Sandoz Confident on Market Acquisition
November 29, 2017
-
REGULATORY New Plan Would Reduce Number of PMP-Eligible Products by 40-50%: MHLW Estimate
November 29, 2017
-
BUSINESS Tagrisso Filed for 1st-Line EGFR-Mutated NSCLC in Japan: AZ
November 28, 2017
-
ORGANIZATION PhRMA Japan Chief “Shocked” by Govt’s PMP Plan, Doesn’t Want It Institutionalized as Proposed
November 27, 2017
-
REGULATORY Draft Outline of Drug Pricing Overhaul Unveiled at Chuikyo; De-Facto Shrinkage for Price Maintenance Scheme Proposed
November 24, 2017
-
REGULATORY Chuikyo Agrees to Define Scope of Off-Year Re-Pricing by 2020-End for 1st Off-Year Revision in April 2021
November 22, 2017
-
TRENDS Large Gap in Performance of New Drugs; Products Including Clenafin, Uptravi Doing Well
November 22, 2017
-
BUSINESS Pfizer Begins Submitting Applications for Biosimilars, Could Be First Major New Drug Maker to Enter Japanese Market
November 21, 2017
-
REGULATORY Govt Plans to Apply 5 Price Bands for Listed Generics in “Off-Year” Revisions, Maintain 50% Rule for 1st Generics in April
November 20, 2017
-
REGULATORY Govt Plans Tiered PMP for Smaller Scope of Products, Post-Z2 Rule for LLPs
November 17, 2017
-
BUSINESS Transfer of LLPs from Chugai “Our Ticket to Admission” into Pharma Business: Taiyo Pharma COO
November 16, 2017
-
REGULATORY Chuikyo OKs Bavencio, Maviret, Ibrance and More for Listing on Nov. 22
November 15, 2017
-
ORGANIZATION Deeper Price Cuts Needed for Off-Patent Brands, Scrap 5-Year Grace Period: Chuikyo Payer Rep
November 14, 2017
-
REGULATORY Pilot CEA Program: Company Data, Third-Party Re-Analysis Data Show Big Gaps for Some Products
November 13, 2017
-
BUSINESS Can Japan’s 1st Enbrel Biosimilar Make Its Mark in RA Follow-On Arena with Self-Injection?
November 10, 2017
-
ACADEMIA In Renewed Attempt, Tokushima Univ. Starts IIT for Eisai-Dropped ALS Drug Candidate
November 9, 2017
-
COMMENTARY Unraveling MHLW/MOF Tug-of-War on Drug Pricing Reform
November 8, 2017
-
BUSINESS 4 Japan Drug Majors See Half-Year Profit Fall on One-Off Factors, but Global Flagships Thrive
November 7, 2017
-
ORGANIZATION Lower Price for Better Medicine? Limit Any CEA-Based Re-Pricing to Premium Portion, PhRMA Says
November 6, 2017
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…